Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 793

1.

Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.

Al Dhaybi O, Bakris GL.

Diabetes Obes Metab. 2020 Apr;22 Suppl 1:69-76. doi: 10.1111/dom.13983. Review.

PMID:
32267074
2.

Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals: The Irrationality of Combination Therapy Avoidance.

Ali WE, Bakris GL.

Hypertension. 2020 Apr;75(4):943-944. doi: 10.1161/HYPERTENSIONAHA.119.14528. Epub 2020 Mar 9. No abstract available.

PMID:
32148130
3.

Improvement of Cardiovascular Functional Reserve After Kidney Transplant-Has the CAPER Been Solved?

Bakris GL, Josephson MA.

JAMA Cardiol. 2020 Feb 5. doi: 10.1001/jamacardio.2019.5874. [Epub ahead of print] No abstract available.

PMID:
32022826
4.

Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study.

Ali W, Gao G, Bakris GL.

Am J Nephrol. 2020;51(3):249-254. doi: 10.1159/000505895. Epub 2020 Jan 24.

PMID:
31982868
5.

Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.

Butler J, Handelsman Y, Bakris G, Verma S.

Eur J Heart Fail. 2020 Jan 11. doi: 10.1002/ejhf.1708. [Epub ahead of print] Review.

PMID:
31926059
6.

Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.

Idzerda NMA, Clegg LE, Hernandez AF, Bakris G, Penland RC, Boulton DW, Bethel MA, Holman RR, Heerspink HJL.

Diabetes Obes Metab. 2020 May;22(5):798-806. doi: 10.1111/dom.13958. Epub 2020 Feb 3.

PMID:
31912603
7.

Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure: Should We Be Surprised?

Polonsky TS, Bakris GL.

JACC Basic Transl Sci. 2019 Dec 23;4(8):973-975. doi: 10.1016/j.jacbts.2019.11.002. eCollection 2019 Dec. No abstract available.

8.

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial.

Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F.

J Am Heart Assoc. 2020 Jan 7;9(1):e012797. doi: 10.1161/JAHA.119.012797. Epub 2020 Jan 4.

9.

Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial.

Bethel MA, Mentz RJ, Merrill P, Buse JB, Chan JC, Goodman SG, Iqbal N, Jakuboniene N, Katona B, Lokhnygina Y, Lopes RD, Maggioni AP, Ohman P, Tankova T, Bakris GL, Hernandez AF, Holman RR.

Diabetes Care. 2020 Feb;43(2):446-452. doi: 10.2337/dc19-1065. Epub 2019 Nov 22.

PMID:
31757838
10.

Major adverse renal events (MARE): A proposal to unifying renal endpoints.

Prischl FC, Rossing P, Bakris G, Mayer G, Wanner C.

Nephrol Dial Transplant. 2019 Nov 11. pii: gfz212. doi: 10.1093/ndt/gfz212. [Epub ahead of print]

PMID:
31711188
11.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.

Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW.

Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11. No abstract available.

PMID:
31707795
12.

Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy.

Bakris G.

J Fam Pract. 2019 Oct;68(8):S1-S6. No abstract available.

PMID:
31697796
13.

Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Alexandrou ME, Papagianni A, Tsapas A, Loutradis C, Boutou A, Piperidou A, Papadopoulou D, Ruilope L, Bakris G, Sarafidis P.

J Hypertens. 2019 Dec;37(12):2307-2324. doi: 10.1097/HJH.0000000000002187.

PMID:
31688290
14.

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B; FIGARO-DKD study investigators.

Am J Nephrol. 2019;50(5):345-356. doi: 10.1159/000503712. Epub 2019 Oct 30.

15.

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G; on behalf of the FIDELIO-DKD study investigators; FIDELIO-DKD study investigators.

Am J Nephrol. 2019;50(5):333-344. doi: 10.1159/000503713. Epub 2019 Oct 25.

16.

Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage.

Baliga RR, Bossone E, Bakris GL.

Heart Fail Clin. 2019 Oct;15(4):xiii-xv. doi: 10.1016/j.hfc.2019.07.001. No abstract available.

PMID:
31472892
17.

Heart Failure and Changes in Kidney Function: Focus on Understanding, Not Reacting.

Polonsky TS, Bakris GL.

Heart Fail Clin. 2019 Oct;15(4):455-461. doi: 10.1016/j.hfc.2019.06.006. Epub 2019 Jul 20. Review.

PMID:
31472881
18.

Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline.

Rosenzweig JL, Bakris GL, Berglund LF, Hivert MF, Horton ES, Kalyani RR, Murad MH, Vergès BL.

J Clin Endocrinol Metab. 2019 Jul 31. pii: jc.2019-01338. doi: 10.1210/jc.2019-01338. [Epub ahead of print]

PMID:
31365087
19.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

20.

Kidney injury is not prevented by hydration alone.

Koyner J, Bakris G.

Eur Heart J. 2019 Oct 7;40(38):3179-3181. doi: 10.1093/eurheartj/ehz462. No abstract available.

PMID:
31263876
21.

Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.

Bakris GL.

Am J Kidney Dis. 2019 Nov;74(5):573-575. doi: 10.1053/j.ajkd.2019.05.009. Epub 2019 Jun 28. No abstract available.

PMID:
31262591
22.

ACC/AHA Versus ESC/ESH on Hypertension Guidelines: JACC Guideline Comparison.

Bakris G, Ali W, Parati G.

J Am Coll Cardiol. 2019 Jun 18;73(23):3018-3026. doi: 10.1016/j.jacc.2019.03.507. Review.

PMID:
31196460
23.

Assessing Wide Pulse Pressure Hypertension: Data Beyond the Guidelines.

Bakris GL, Laffin LJ.

J Am Coll Cardiol. 2019 Jun 11;73(22):2856-2858. doi: 10.1016/j.jacc.2019.03.494. No abstract available.

24.

The Management of Hypertension in 2018: What Should the Targets Be?

Ali W, Bakris G.

Curr Hypertens Rep. 2019 Apr 25;21(6):41. doi: 10.1007/s11906-019-0946-7. Review.

PMID:
31025203
25.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
26.

Perspective on the New Blood-Pressure Guidelines.

Bakris G, Sorrentino M.

Eur Heart J. 2018 Sep 1;39(33):3008-3009. doi: 10.1093/eurheartj/ehy280. No abstract available.

PMID:
30990868
27.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

28.

Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.

Bakris G.

Circ Res. 2019 Mar 29;124(7):969-971. doi: 10.1161/CIRCRESAHA.118.314664. No abstract available.

PMID:
30920926
29.

Redefining diuretics use in hypertension: why select a thiazide-like diuretic?

Burnier M, Bakris G, Williams B.

J Hypertens. 2019 Aug;37(8):1574-1586. doi: 10.1097/HJH.0000000000002088.

30.

Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia.

Vijayakumar S, Butler J, Bakris GL.

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A20-A27. doi: 10.1093/eurheartj/suy030. Epub 2019 Feb 26.

31.

Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis.

Sternlicht H, Bakris GL.

Curr Hypertens Rep. 2019 Feb 12;21(2):12. doi: 10.1007/s11906-019-0920-4. Review.

PMID:
30747296
32.

Novel therapies for diabetic kidney disease.

Cherney DZI, Bakris GL.

Kidney Int Suppl (2011). 2018 Jan;8(1):18-25. doi: 10.1016/j.kisu.2017.10.005. Epub 2017 Dec 29. Review.

33.

Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes.

Bakris GL.

Kidney Int Suppl (2011). 2018 Jan;8(1):1. doi: 10.1016/j.kisu.2017.10.002. Epub 2017 Dec 29. No abstract available.

34.

Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines? - An Asian Perspective.

Ihm SH, Bakris G, Sakuma I, Sohn IS, Koh KK.

Circ J. 2019 Feb 25;83(3):504-510. doi: 10.1253/circj.CJ-18-1293. Epub 2018 Dec 29. Review.

35.

MASked-unconTrolled hypERtension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol.

Parati G, Agabiti-Rosei E, Bakris GL, Bilo G, Branzi G, Cecchi F, Chrostowska M, De la Sierra A, Domenech M, Dorobantu M, Faria T, Huo Y, Jelaković B, Kahan T, Konradi A, Laurent S, Li N, Madan K, Mancia G, McManus RJ, Modesti PA, Ochoa JE, Octavio JA, Omboni S, Palatini P, Park JB, Pellegrini D, Perl S, Podoleanu C, Pucci G, Redon J, Renna N, Rhee MY, Rodilla Sala E, Sanchez R, Schmieder R, Soranna D, Stergiou G, Stojanovic M, Tsioufis K, Valsecchi MG, Veglio F, Waisman GD, Wang JG, Wijnmaalen P, Zambon A, Zanchetti A, Zhang Y.

BMJ Open. 2018 Dec 19;8(12):e021038. doi: 10.1136/bmjopen-2017-021038.

36.

Creatinine Bump Following Antihypertensive Therapy.

Bakris GL, Agarwal R.

Hypertension. 2018 Dec;72(6):1274-1276. doi: 10.1161/HYPERTENSIONAHA.118.12051. No abstract available.

PMID:
30571245
37.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
38.

Intradialytic Hypotension: Is Midodrine the Answer?

Hammes M, Bakris GL.

Am J Nephrol. 2018;48(5):378-380. doi: 10.1159/000494805. Epub 2018 Nov 13. No abstract available.

39.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

de Zeeuw D, Renfurm RW, Bakris G, Rossing P, Perkovic V, Hou FF, Nangaku M, Sharma K, Heerspink HJL, Garcia-Hernandez A, Larsson TE.

Lancet Diabetes Endocrinol. 2018 Dec;6(12):925-933. doi: 10.1016/S2213-8587(18)30289-4. Epub 2018 Nov 6.

PMID:
30413396
40.

Ambulatory Blood Pressure Monitoring.

Polonsky TS, Bakris GL.

JAMA. 2018 Nov 6;320(17):1807-1808. doi: 10.1001/jama.2018.14856. No abstract available.

PMID:
30398582
41.

Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial.

White WB, Jalil F, Cushman WC, Bakris GL, Bergenstal R, Heller SR, Liu Y, Mehta C, Zannad F, Cannon CP.

J Am Heart Assoc. 2018 Oct 16;7(20):e009114. doi: 10.1161/JAHA.118.009114.

42.

Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN, White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council.

Hypertension. 2018 Nov;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084.

43.

Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension?

Laffin LJ, Bakris GL.

Hypertension. 2018 Oct;72(4):836-838. doi: 10.1161/HYPERTENSIONAHA.118.11207. No abstract available.

44.

Erratum.

Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G.

Nephrol Dial Transplant. 2018 Sep 19. doi: 10.1093/ndt/gfy311. [Epub ahead of print] No abstract available.

PMID:
30239875
45.

Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension.

Ferdinand KC, Bakris GL, Cushman WC, Weber MA, Lloyd E, Wu J, White WB.

Am J Cardiol. 2018 Nov 1;122(9):1496-1505. doi: 10.1016/j.amjcard.2018.07.022. Epub 2018 Aug 4.

46.

Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events.

Bakris GL, Polonsky TS.

J Am Coll Cardiol. 2018 Sep 11;72(11):1224-1226. doi: 10.1016/j.jacc.2018.07.016. No abstract available.

47.

The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients.

Sarafidis PA, Loutradis C, Karpetas A, Tzanis G, Bikos A, Raptis V, Syrgkanis C, Liakopoulos V, Papagianni A, Bakris G, Parati G.

Nephrol Dial Transplant. 2019 Mar 1;34(3):515-523. doi: 10.1093/ndt/gfy247.

PMID:
30184172
48.

Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used.

Ali WE, Bakris GL.

Eur Heart J. 2018 Oct 21;39(40):3662-3663. doi: 10.1093/eurheartj/ehy500. No abstract available.

PMID:
30137271
49.

Renal denervation: one step backwards, three steps forward.

Schlaich MP, Bakris GL.

Nat Rev Nephrol. 2018 Oct;14(10):602-604. doi: 10.1038/s41581-018-0040-4. No abstract available.

PMID:
29980772
50.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.

Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.

Supplemental Content

Loading ...
Support Center